To better understand the fate of LIN28B-expressing AML cells, we switched to a DOX-inducible model—Vav1-Cre; Rosa26LoxP-STOP-LoxP-rtTA; Col1a1TetO_Lin28b (Tet-ON LIN28B)—to afford more precise temporal control of LIN28B expression. The gene discussed is MAP6; the disease is acute myeloid leukemia.